DOAC News | DOAC

New aspirin cessation questions available

Submitted by shensky on Mon, 2026-05-04 14:26

We have started monitoring why patients in the DOAC registry are stopping aspirin.

In the Follow-up only, Section 5: Medications, if any of the aspirin dosing choices (81mg, 162mg or 365mg) are to be “unchecked” because the aspirin was discontinued or stopped a “NOTE” will appear in blue:

NOTE: Be sure to fill out Discontinuation of Aspirin below

DOSE Protocol updates posted 12/13/2025

Submitted by admin on Tue, 2025-12-16 14:17

Download the update here.

DOAC Dataform and DOSE Protocol Updated 12/02/2025

Submitted by admin on Thu, 2025-12-04 16:00

We have added lecanemab (Leqembi) to the Baseline and Follow-up Medication Section and as a DOSE alert to avoid this medication since it may cause increased bleeding. Download the dataform here and DOSE protocol here.

WATCH Baseline patients will now be linked to the DOAC registry...

Submitted by admin on Mon, 2025-11-24 21:23

WATCH Baseline patients will now be linked to the DOAC registry and entered into the database only if they meet the specific eligibility criteria.

DOAC Dataform and DOSE Protocol Updated 09/24/2025

Submitted by admin on Tue, 2025-10-07 14:24

We have added donanemab (Kisunla) to the Baseline and Follow-up Medication Section and as a DOSE alert to avoid this medication since it may cause increased bleeding. Download the dataform here and DOSE protocol here.

DOAC Dataform and Dictionary Updated 09/12/2025

Submitted by admin on Fri, 2025-09-12 13:11

The data form document and data dictionary have been updated. We have included immunotherapy alongside chemotherapy for cancer treatment in Comorbidities. Download it here and here.

DOAC Dataform Updated 08/20/2024

Submitted by admin on Thu, 2024-08-22 17:23

The data form document has been updated. We have added specific questions regarding hematuria adverse events in the follow-up form. Download it here.

DOSE Protocol updates posted 08/02/2024

Submitted by admin on Wed, 2024-08-07 17:04

Download the update here.

DOSE Protocol updates posted 02/16/2024

Submitted by admin on Mon, 2024-02-19 13:11

The document was revised, for dabigatran (all Indications) and rivaroxaban (all Indications except CAD & PAD) to add the following statement: “Consider alternative anticoagulation in patients who develop significant acute renal failure”

Download the update here.

DOSE Protocol updates posted 01/27/2024

Submitted by admin on Mon, 2024-01-29 11:10

Page 3 of the document has been revised, for all DOACs, with the following “Not recommended as first-line therapy in patients with antiphospholipid antibody syndrome (APS)”.

Download the update here.